文献速递主动脉疾病外周动脉疾病颈动脉与弓上血管

血管手术后围术期心肌梗死出院抗血小板与他汀治疗不足

Underutilization of antiplatelet and statin therapy after postoperative myocardial infarction following vascular surgery.
PubMed 文献 · J Vasc Surg · 2017-08-19

基于VQI 2005至2015年1749例血管手术后发生围术期心肌梗死(POMI)的患者,分析出院时抗血小板与他汀使用情况。

要点

  • 血管手术后POMI患者出院时26%未接受抗血小板联合他汀治疗。
  • 出院联合抗血小板加他汀与较低远期死亡率相关(HR 0.72)。
  • POMI后心脏药物使用存在区域和手术类型差异。

核心结论

  • 血管手术后POMI患者出院时抗血小板联合他汀治疗不足,且与较高远期死亡率相关。

研究设计与样本

  • 多中心注册研究,纳入VQI 2005至2015年1749例血管手术后发生POMI的手术。

主要发现

  • 出院时阿司匹林使用率81%,P2Y12抑制剂38%,他汀76%,抗血小板联合他汀74%。
  • 出院时26%未接受抗血小板联合他汀治疗,单联抗血小板(50%)比双联(35%)更常见(P<.001)。
  • 颈动脉内膜切除术后出院心脏药物使用率80%, infrainguinal bypass 78%,suprainguinal bypass 72%,EVAR 71%,开放腹主动脉瘤修复59%(P<.001)。
  • 联合抗血小板加他汀组平均随访5.5年生存率79%,非联合或无治疗组平均随访4.9年生存率69%(log-rank P=.001)。
  • 校正协变量后,出院联合抗血小板加他汀与较低远期死亡率相关(HR 0.72,95%CI 0.56-0.93,P=.01)。

关键数值与推荐

  • 出院心脏药物定义为单联抗血小板(阿司匹林或P2Y12抑制剂)或双联抗血小板(阿司匹林加P2Y12抑制剂)联合他汀治疗。
  • 区域间出院心脏药物使用率范围33%至100%(P=.05)。

临床怎么用

  • 血管手术后发生POMI的患者出院时应评估并优化抗血小板联合他汀治疗。
  • 关注手术类型和区域差异,作为质量改进的靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The objective of this study was to investigate adherence to practice guidelines for antiplatelet and statin use after postoperative myocardial infarction (POMI) and its effect on late mortality following vascular surgery in a multicenter registry. METHODS: Antiplatelet and statin use was examined in 1749 vascular surgery procedures with POMI within the Vascular Quality Initiative (VQI) from 2005 to 2015. Our primary aim was to assess cardiac medication (CM) use at discharge, defined as (1) single antiplatelet therapy (SAPT; aspirin or P2Y12 inhibitor) or dual antiplatelet therapy (DAPT; aspirin and P2Y12 inhibitor) and (2) statin therapy. Long-term mortality in patients with POMI was analyzed on the basis of discharge CM. A proportional hazards model was developed to control for factors associated with mortality. Regional differences in CM use at discharge after POMI were compared. RESULTS: Overall discharge CM use after POMI included aspirin (81%), P2Y12 inhibitor (38%), statin therapy (76%), and combined antiplatelet and statin (74%). At discharge, 26% of patients were not receiving combined antiplatelet and statin therapy. SAPT (50%) was more common than DAPT (35%; P < .001). Patients with POMI undergoing carotid endarterectomy were more likely to be discharged on CM (80%) compared with patients undergoing infrainguinal bypass (78%), suprainguinal bypass (72%), endovascular aneurysm repair (71%), and open abdominal aortic aneurysm repair (59%; P < .001). Patients receiving SAPT or DAPT plus statin therapy had improved survival (79%) compared with those receiving noncombination or no therapy (69%) with mean follow-up of 5.5 years and 4.9 years, respectively (log-rank, P = .001). After adjustment for covariates including preoperative medications, treatment with SAPT or DAPT plus statin at discharge was associated with lower late mortality compared with noncombination or no therapy (hazard ratio, 0.72; 95% confidence interval, 0.56-0.93; P = .01). Regional variation in CM at discharge following POMI was also observed with a range of 33% to 100% (P = .05). CONCLUSIONS: Within the VQI, regional and procedure-specific variation exists in CM regimen after POMI following vascular surgery. Absence of combined antiplatelet and statin therapy at discharge after POMI was associated with higher late mortality and represents an area for quality improvement in the care of these patients.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Steely AM, Callas PW, Hohl PK, et al. Underutilization of antiplatelet and statin therapy after postoperative myocardial infarction following vascular surgery. J Vasc Surg. 2017. PMID: 28830706. doi:10.1016/j.jvs.2017.06.093

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。